A Phase 2 interventional study of Roflumilast Foam 0.3% and Vehicle foam in Seborrheic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dermatitis, Seborrheic with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Dermatitis, Seborrheic · United States.
Among the 19 studies in Dermatitis, Seborrheic with a site in United States, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 13th registered.
58 studies on the registry are indexed under Dermatitis, Seborrheic; 7 are open to participants now.
Browse Dermatitis, Seborrheic studies →1 of the 19 studies in Dermatitis, Seborrheic with a site in United States is open now. Recruiting first, the newest first:
Integrative Skin Science and Research · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Dermatitis, Seborrheic studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 77 across 47 interventional studies indexed under Dermatitis, Seborrheic.
Median enrollment 62 across the 18 interventional studies, 32 across the 1 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
Arcutis Biotherapeutics, Inc. has 3 studies filed under Dermatitis, Seborrheic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Dermatitis, Seborrheic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants apply roflumilast foam 0.3% once daily (QD) to all areas of seborrheic dermatitis once daily for 8 weeks.
Drug: Roflumilast Foam 0.3%
Participants apply inactive vehicle foam matched to roflumilast foam QD for 8 weeks.
Drug: Vehicle foam
Roflumilast foam for topical application.
Also known as: ARQ-154
Vehicle foam for topical application.
Also known as: Placebo
Achievement of Investigator Global Assessment (IGA) Success at Week 8
The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.
Time frame: Week 8
Achievement of IGA Success at Weeks 2 and 4
The number of participants achieving "success" in IGA assessment of disease severity at Weeks 2 and 4 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.
Time frame: Weeks 2 and 4
Change From Baseline in Overall Assessment of Erythema Score
The mean (SD) change from baseline in Overall Assessment of Erythema score at Weeks 2, 4, and 8 is shown. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.
Time frame: Weeks 2, 4, and 8
Achievement of Overall Assessment of Erythema Success
The number of participants achieving "success" in Overall Assessment of Erythema at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an overall score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Erythema is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.
Time frame: Weeks 2, 4, and 8
Change From Baseline in Overall Assessment of Scaling Score
The mean (SD) change from baseline in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is shown. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.
Time frame: Weeks 2, 4, and 8
Achievement of Overall Assessment of Scaling Success
The number of participants achieving "success" in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an Overall Assessment of Scaling score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.
Time frame: Weeks 2, 4, and 8
Change From Baseline in Worst Itch Numeric Rating Scale (WI-NRS) Score
The change from baseline in WI-NRS is shown. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Negative values represent a decrease in worst itch from baseline, and positive values indicate an increase.
Time frame: Weeks 2, 4, and 8
Achievement of WI-NRS Success
The number of participants achieving WI-NRS "success" at Weeks 2, 4, and 8 is presented. Success was defined as achievement of a ≥4-point improvement from baseline WI-NRS score. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.
Time frame: Weeks 2, 4, and 8
| Milestone | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Started | 154 | 72 |
| Completed | 141 | 67 |
| Not completed | 13 | 5 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lost to follow-up | 6 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Participant incarcerated | 1 | 0 |
The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Investigator Global Assessment (IGA) Success at Week 8 | 104 | 27 |
The number of participants achieving "success" in IGA assessment of disease severity at Weeks 2 and 4 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | 51 | 10 |
| Week 4 | 81 | 19 |
The mean (SD) change from baseline in Overall Assessment of Erythema score at Weeks 2, 4, and 8 is shown. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | -1.0 ± 0.73 | -0.4 ± 0.65 |
| Week 4 | -1.3 ± 0.73 | -0.7 ± 0.68 |
| Week 8 | -1.4 ± 0.78 | -0.8 ± 0.85 |
The number of participants achieving "success" in Overall Assessment of Erythema at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an overall score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Erythema is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | 34 | 4 |
| Week 4 | 51 | 7 |
| Week 8 | 63 | 14 |
The mean (SD) change from baseline in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is shown. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.
| Score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | -1.0 ± 0.77 | -0.6 ± 0.78 |
| Week 4 | -1.3 ± 0.76 | -0.8 ± 0.81 |
| Week 8 | -1.5 ± 0.75 | -1.0 ± 0.83 |
The number of participants achieving "success" in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an Overall Assessment of Scaling score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | 40 | 10 |
| Week 4 | 59 | 14 |
| Week 8 | 63 | 14 |
The change from baseline in WI-NRS is shown. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Negative values represent a decrease in worst itch from baseline, and positive values indicate an increase.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | -3.0 ± 2.80 | -1.7 ± 2.08 |
| Week 4 | -3.5 ± 2.72 | -1.9 ± 2.22 |
| Week 8 | -3.7 ± 2.83 | -2.0 ± 2.37 |
The number of participants achieving WI-NRS "success" at Weeks 2, 4, and 8 is presented. Success was defined as achievement of a ≥4-point improvement from baseline WI-NRS score. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | 65 | 13 |
| Week 4 | 70 | 15 |
| Week 8 | 73 | 18 |
Collected over Up to ~63 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Foam 0.3% | 0/154 (0%) | 0/154 (0%) | 0/154 (0%) |
| Vehicle Foam | 0/72 (0%) | 0/72 (0%) | 0/72 (0%) |
| Age, Continuous(years) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Mean | 45.3 ± 17.01 | 44.2 ± 16.27 | 44.9 ± 16.75 |
| Sex: Female, Male(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Female | 78 | 32 | 110 |
| Male | 76 | 40 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 16 | 45 |
| Not Hispanic or Latino | 125 | 56 | 181 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| American-Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 7 | 1 | 8 |
| Black or African-American | 17 | 6 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 123 | 62 | 185 |
| Other | 1 | 2 | 3 |
| More than One Race | 5 | 1 | 6 |
| Investigator Global Assessment (IGA) Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| 0 Completely Clear | 0 | 0 | 0 |
| 1 Almost Clear | 0 | 0 | 0 |
| 2 Mild | 0 | 0 | 0 |
| 3 Moderate | 141 | 69 | 210 |
| 4 Severe | 13 | 3 | 16 |
| Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| 0 | 7 | 2 | 9 |
| 1 | 6 | 2 | 8 |
| 2 | 9 | 5 | 14 |
| 3 | 7 | 4 | 11 |
| 4 | 18 | 8 | 26 |
| 5 | 13 | 11 | 24 |
| 6 | 20 | 5 | 25 |
| 7 | 27 | 17 | 44 |
| 8 | 24 | 16 | 40 |
| 9 | 14 | 0 | 14 |
| 10 | 9 | 2 | 11 |
| Overall Assessment of Erythema Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| None | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
| Moderate | 135 | 66 | 201 |
| Severe | 19 | 6 | 25 |
| Overall Assessment of Scaling Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| None | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
| Moderate | 130 | 58 | 188 |
| Severe | 24 | 14 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Aug 2020, 8 months.
Results were first posted in Jul 2023, 2 years 10 months after primary completion. A results delay was requested in Jun 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARQ-154
Arcutis Biotherapeutics, Inc. →